| Citation: |
ZHAO Dongfang, ZHU Yafang, XING Man, PANG Conghui, LIU Junxia, ZHANG Shuting. Impact of smoking cessation on phenotype of high-resolution computed tomography and frequency of acute exacerbation in smokers with chronic obstructive pulmonary disease[J]. Journal of Clinical Medicine in Practice, 2025, 29(3): 64-69. DOI: 10.7619/jcmp.20243936
|
To investigate the impact of smoking cessation on high-resolution computed tomography (HRCT) phenotypes in smokers with chronic obstructive pulmonary disease (COPD) and its relationship with the frequency of acute exacerbations.
A retrospective study was conducted in 237 smokers with COPD who could cooperate with a 1-year follow-up. Among them, 160 patients underwent a comprehensive 1-year smoking cessation intervention, and were divided into smoking cessation failure group (87 patients) and smoking cessation success group (73 patients) based on whether they successfully quited smoking. The remaining 77 smokers with COPD who did not receive smoking cessation intervention were designated as smoking group. HRCT phenotypes, total lung volume (TLV), total emphysema volume (TEV), emphysema index (EI) and the number of acute exacerbation at different time points were compared among the three groups. Pearson correlation analysis was used to explore the correlation between smoking cessation and the number of acute exacerbations.
There was no statistically significant difference in the proportion of A phenotype patients among the three groups before intervention and at 3 and 6 months of intervention (P>0.05). At the 9th and 12th months of intervention, the proportion of patients with A phenotype in the smoking group was lower than that in the smoking cessation failure group and smoking cessation success group (P < 0.05). Before the intervention and at the 3rd, 6th and 9th months of intervention, there were no statistically significant differences in the proportion of patients with E phenotype among the three groups (P>0.05). Before intervention and at the 3rd and 6th months of intervention, there were no statistically significant differences in the proportion of patients with M phenotype among the three groups (P>0.05). At the 9th and 12th months of intervention, the proportion of patients with M phenotype in the smoking group was higher than that in the smoking cessation failure group and smoking cessation success group (P < 0.05). Before intervention, there were no statistically significant differences in TLV, TEV and EI among the three groups (P>0.05). One year after the intervention, TLV, TEV and EI in the smoking cessation failure group and smoking cessation success group were lower than those in the smoking group (P < 0.05). At the 3rd, 6th, 9th and 12th months of intervention, the number of acute exacerbations in the the smoking cessation failure group and smoking cessation success group was less than that in the smoking group (P < 0.05). At the 9th and 12th months of intervention, the number of acute exacerbation in the smoking cessation success group was less than that in the smoking cessation failure group (P < 0.05). The results of Pearson correlation analysis showed that smoking cessation was negatively correlated with the number of acute exacerbation in smokers with COPD (P < 0.05), and this negative correlation gradually increased with the extension of smoking cessation duration.
Smoking cessation can improve HRCT phenotypes and effectively reduce the number of acute exacerbation in smokers with COPD.
| [1] |
UWAGBOE I, ADCOCK I M, LO BELLO F, et al. New drugs under development for COPD[J]. Minerva Med, 2022, 113(3): 471-496.
|
| [2] |
HOGG J C, TIMENS W. The pathology of chronic obstructive pulmonary disease[J]. Annu Rev Pathol, 2009, 4: 435-459. doi: 10.1146/annurev.pathol.4.110807.092145
|
| [3] |
MACINTYRE N R. Acute hypercapnic respiratory failure in COPD[J]. Respir Care, 2023, 68(7): 973-982. doi: 10.4187/respcare.10560
|
| [4] |
SILVERMAN E K. Genetics of copd[J]. Annu Rev Physiol, 2020, 82: 413-431. doi: 10.1146/annurev-physiol-021317-121224
|
| [5] |
LU D, CHEN L, FAN C, et al. The value of impulse oscillometric parameters and quantitative HRCT parameters in differentiating asthma-COPD overlap from COPD[J]. Int J Chron Obstruct Pulmon Dis, 2021, 16: 2883-2894. doi: 10.2147/COPD.S331853
|
| [6] |
ZHU D, QIAO C, DAI H L, et al. Diagnostic efficacy of visual subtypes and low attenuation area based on HRCT in the diagnosis of COPD[J]. BMC Pulm Med, 2022, 22(1): 81. doi: 10.1186/s12890-022-01875-6
|
| [7] |
YANG Y, LI W, KANG Y, et al. A novel lung radiomics feature for characterizing resting heart rate and COPD stage evolution based on radiomics feature combination strategy[J]. Math Biosci Eng, 2022, 19(4): 4145-4165. doi: 10.3934/mbe.2022191
|
| [8] |
孔德昭, 王科雯, 罗文晔, 等. 慢性阻塞性肺疾病急性加重期诊疗指南评价与综合分析[J]. 中国中医基础医学杂志, 2023, 29(8): 1307-1317.
|
| [9] |
KAHNERT K, JÖRRES R A, BEHR J, et al. The diagnosis and treatment of COPD and its comorbidities[J]. Dtsch Arztebl Int, 2023, 120(25): 434-444.
|
| [10] |
CHRISTENSON S A, SMITH B M, BAFADHEL M, et al. Chronic obstructive pulmonary disease[J]. Lancet, 2022, 399(10342): 2227-2242. doi: 10.1016/S0140-6736(22)00470-6
|
| [11] |
VOGELMEIER C F, ROMÁN-RODRÍGUEZ M, SINGH D, et al. Goals of COPD treatment: Focus on symptoms and exacerbations[J]. Respir Med, 2020, 166: 105938. doi: 10.1016/j.rmed.2020.105938
|
| [12] |
UPADHYAY P, WU C W, PHAM A, et al. Animal models and mechanisms of tobacco smoke-induced chronic obstructive pulmonary disease (COPD)[J]. J Toxicol Environ Health B Crit Rev, 2023, 26(5): 275-305. doi: 10.1080/10937404.2023.2208886
|
| [13] |
VILA M, FANER R, AGUSTÍ A. Beyond the COPD-tobacco binomium: new opportunities for the prevention and early treatment of the disease[J]. Med Clin: Barc, 2022, 159(1): 33-39. doi: 10.1016/j.medcli.2022.01.021
|
| [14] |
YANG I A, JENKINS C R, SALVI S S. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment[J]. Lancet Respir Med, 2022, 10(5): 497-511. doi: 10.1016/S2213-2600(21)00506-3
|
| [15] |
QI C, SUN S W, XIONG X Z. From COPD to lung cancer: mechanisms linking, diagnosis, treatment, and prognosis[J]. Int J Chron Obstruct Pulmon Dis, 2022, 17: 2603-2621. doi: 10.2147/COPD.S380732
|
| [16] |
HAYNES J M, KAMINSKY D A, RUPPEL G L. The role of pulmonary function testing in the diagnosis and management of COPD[J]. Respir Care, 2023, 68(7): 889-913. doi: 10.4187/respcare.10757
|
| [17] |
LI Y N, SHI G C, GUAN J. Advances in chest imaging in early chronic obstructive pulmonary disease[J]. Zhonghua Jie He He Hu Xi Za Zhi, 2023, 46(12): 1266-1271.
|
| [18] |
XIE H Y, ZHAO Z, ZHANG W J, et al. Quantitative analysis of lung function and airway remodeling using ventilation/perfusion single photon emission tomography/computed tomography and HRCT in patients with chronic obstructive pulmonary disease and asthma[J]. Ann Nucl Med, 2023, 37(9): 504-516. doi: 10.1007/s12149-023-01848-7
|
| [19] |
CHRISTENSON S A. COPD phenotyping[J]. Respir Care, 2023, 68(7): 871-880. doi: 10.4187/respcare.11035
|
| [20] |
HERING T. Höchste priorität Bei COPD: tabakentwöhnung[J]. MMW Fortschr Der Med, 2021, 163(10): 62-63. doi: 10.1007/s15006-021-9893-8
|
| 1. |
杨虹，季红珍，黄萍，陈善美. 腹部联合阴道超声用于生育“二孩”或“三孩”瘢痕子宫孕妇孕早期胎盘植入诊断的价值. 生殖医学杂志. 2024(06): 813-816 .
| |
| 2. |
谢贤海，郑宗杰. 经阴道彩色多普勒超声心动图诊断宫颈部胎盘植入的效果. 医疗装备. 2023(05): 66-69 .
| |
| 3. |
时明芳，常书娟，张聪祎. 超声评分法联合血浆人胎盘催乳素水平检测对前置胎盘合并胎盘植入的诊断价值. 中国医药导报. 2023(09): 97-100 .
| |
| 4. |
高莉，张玉琴，薛祖兵，王小漫，徐庆. 产前不同超声特征对瘢痕子宫胎盘植入的评价分析. 生殖医学杂志. 2023(05): 759-762 .
| |
| 5. |
孙雪，高霞，刘博，周春花，李云鹏. 孕妇胎盘内部血流参数与妊高症关系研究. 西部医学. 2023(05): 765-769 .
| |
| 6. |
张敬丽，谷小乐，元丽芝. 二维超声及彩色多普勒超声诊断孕晚期胎盘植入的价值. 临床医学. 2022(10): 81-83 .
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: